Crovalimab

Crovalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting C5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Crovalimab, a Sequential Monoclonal Antibody Recycling Technology (SMART) antibody was engineered for extended self-administered subcutaneous dosing of small volumes in diseases amenable for C5 inhibition.

Target	C5
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1917321-26-6
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on C5

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue